Search

Displaying results 2751 - 2760 of 10000 in total
  1. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. … This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.

  2. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November … [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity

  3. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs. … Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.

  4. Drug

    Metiamide

    go.drugbank.com/drugs/DB08805
    Experimental

    Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.

  5. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.

  6. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.

  7. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    Pharmacologic estrogen products are available in a variety of formats. … However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control

  9. Drug

    Oxymetholone

    go.drugbank.com/drugs/DB06412
    ApprovedIllicit

    in malnourished or underdeveloped patients. … Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth

  10. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps … Regardless, protamine sulfate continues to see contemporary use given its genuine effectiveness in reversing heparin effects.